K. Yan, K. Yang, and J. Rich, The evolving landscape of glioblastoma stem cells, Current Opinion in Neurology, vol.26, issue.6, pp.701-707, 2013.
DOI : 10.1097/WCO.0000000000000032

X. Yuan, J. Curtin, Y. Xiong, G. Liu, S. Waschsmann-hogiu et al., Isolation of cancer stem cells from adult glioblastoma multiforme, Oncogene, vol.23, issue.58, pp.9392-9400, 2004.
DOI : 10.1038/sj.onc.1208311

E. Galan-moya, L. Guelte, A. Fernandes, E. Thirant, C. Dwyer et al., Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway, EMBO reports, vol.19, issue.5, pp.470-476, 2011.
DOI : 10.1038/sj.onc.1208311

E. Galan-moya, L. Treps, L. Oliver, H. Chneiweiss, F. Vallette et al., Endothelial Secreted Factors Suppress Mitogen Deprivation-Induced Autophagy and Apoptosis in Glioblastoma Stem-Like Cells, PLoS ONE, vol.13, issue.3, p.93505, 2014.
DOI : 10.1371/journal.pone.0093505.g004
URL : https://hal.archives-ouvertes.fr/inserm-01075054

C. Calabrese, H. Poppleton, M. Kocak, T. Hogg, C. Fuller et al., A Perivascular Niche for Brain Tumor Stem Cells, Cancer Cell, vol.11, issue.1, pp.69-82, 2007.
DOI : 10.1016/j.ccr.2006.11.020

T. Batchelor, A. Sorensen, E. Di-tomaso, W. Zhang, D. Duda et al., AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients, Cancer Cell, vol.11, issue.1, pp.83-95, 2007.
DOI : 10.1016/j.ccr.2006.11.021

O. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran et al., Bevacizumab plus Radiotherapy???Temozolomide for Newly Diagnosed Glioblastoma, New England Journal of Medicine, vol.370, issue.8, pp.709-722, 2014.
DOI : 10.1056/NEJMoa1308345
URL : http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-89503

M. Gilbert, J. Dignam, T. Armstrong, J. Wefel, D. Blumenthal et al., A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, New England Journal of Medicine, vol.370, issue.8, pp.699-708, 2014.
DOI : 10.1056/NEJMoa1308573

A. Guelte, E. Galan-moya, J. Dwyer, L. Treps, G. Kettler et al., Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation, Journal of Cell Science, vol.125, issue.17, pp.4137-4146, 2012.
DOI : 10.1242/jcs.108282

F. Maione, F. Molla, C. Meda, R. Latini, L. Zentilin et al., Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models, Journal of Clinical Investigation, vol.119, pp.3356-3372, 2009.
DOI : 10.1172/JCI36308DS1

A. Casazza, X. Fu, I. Johansson, L. Capparuccia, F. Andersson et al., Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.31, issue.4, pp.741-749, 2011.
DOI : 10.1161/ATVBAHA.110.211920

L. Acevedo, S. Barillas, S. Weis, J. Gothert, and D. Cheresh, Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor, Blood, vol.111, issue.5, pp.2674-2680, 2008.
DOI : 10.1182/blood-2007-08-110205

A. Casazza, D. Laoui, M. Wenes, S. Rizzolio, N. Bassani et al., Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity, Cancer Cell, vol.24, issue.6, pp.695-709, 2013.
DOI : 10.1016/j.ccr.2013.11.007

J. Skog, T. Wurdinger, S. Van-rijn, D. Meijer, L. Gainche et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nature Cell Biology, vol.94, issue.12, pp.1470-1476, 2008.
DOI : 10.1371/journal.pone.0000571
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423894

P. Vader, X. Breakefield, and M. Wood, Extracellular vesicles: emerging targets for cancer therapy, Trends in Molecular Medicine, vol.20, issue.7, pp.385-393, 2014.
DOI : 10.1016/j.molmed.2014.03.002

M. Colombo, G. Raposo, and C. Thery, Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles, Annual Review of Cell and Developmental Biology, vol.30, issue.1, pp.255-289, 2014.
DOI : 10.1146/annurev-cellbio-101512-122326

P. Kucharzewska, H. Christianson, J. Welch, K. Svensson, E. Fredlund et al., Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development, Proceedings of the National Academy of Sciences, vol.110, issue.18, pp.7312-7317, 2013.
DOI : 10.1073/pnas.1220998110

H. Shao, J. Chung, L. Balaj, A. Charest, D. Bigner et al., Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy, Nature Medicine, vol.52, issue.12, pp.1835-1840, 2012.
DOI : 10.1002/anie.201100101

C. Thirant, E. Galan-moya, L. Dubois, S. Pinte, P. Chafey et al., Differential Proteomic Analysis of Human Glioblastoma and Neural Stem Cells Reveals HDGF as a Novel Angiogenic Secreted Factor, STEM CELLS, vol.30, issue.Pt 1, pp.845-853, 2012.
DOI : 10.1002/stem.1062

J. Gavard and J. Gutkind, VEGF controls endothelial-cell permeability by promoting the ??-arrestin-dependent endocytosis of VE-cadherin, Nature Cell Biology, vol.280, issue.11, pp.1223-1234, 2006.
DOI : 10.1038/ncb1486

R. Crescitelli, C. Lasser, T. Szabo, A. Kittel, M. Eldh et al., Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes, Journal of Extracellular Vesicles, vol.8, issue.1, p.20677, 2013.
DOI : 10.3402/jev.v1i0.19179

A. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-welsh, VEGF receptor signalling ??? in control of vascular function, Nature Reviews Molecular Cell Biology, vol.99, issue.5, pp.359-371, 2006.
DOI : 10.1038/nrm1911

Q. Chanthery, Y. Liang, W. Stawicki, S. Mak, J. Rathore et al., Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth, Cancer Cell, vol.11, pp.53-67, 2007.

Y. Piao, J. Liang, L. Holmes, A. Zurita, V. Henry et al., Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype, Neuro-Oncology, vol.14, issue.11, pp.1379-1392, 2012.
DOI : 10.1093/neuonc/nos158

X. Chen, L. Zhang, I. Zhang, J. Liang, H. Wang et al., RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma, Cancer Research, vol.74, issue.24, pp.7285-7297, 2014.
DOI : 10.1158/0008-5472.CAN-14-1240
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268204

F. Maione, S. Capano, D. Regano, L. Zentilin, M. Giacca et al., Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice, Journal of Clinical Investigation, vol.122, issue.5, pp.1832-1848, 2012.
DOI : 10.1172/JCI58976DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336974

J. Vredenburgh, A. Desjardins, J. Herndon, M. J. Reardon, D. Quinn et al., Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.25, issue.30, pp.4722-4729, 2007.
DOI : 10.1200/JCO.2007.12.2440

H. Friedman, M. Prados, P. Wen, T. Mikkelsen, D. Schiff et al., Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.28, pp.4733-4740, 2009.
DOI : 10.1200/JCO.2008.19.8721

T. Kreisl, L. Kim, K. Moore, P. Duic, R. C. Stroud et al., Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.5, pp.740-745, 2009.
DOI : 10.1200/JCO.2008.16.3055

A. Lai, A. Tran, P. Nghiemphu, W. Pope, O. Solis et al., Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme, Journal of Clinical Oncology, vol.29, issue.2, pp.142-148, 2011.
DOI : 10.1200/JCO.2010.30.2729

A. Narayana, D. Gruber, S. Kunnakkat, J. Golfinos, E. Parker et al., A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma, Journal of Neurosurgery, vol.116, issue.2, pp.341-345, 2012.
DOI : 10.3171/2011.9.JNS11656

J. Dwyer, J. Hebda, L. Guelte, A. Galan-moya, E. Smith et al., Glioblastoma Cell-Secreted Interleukin-8 Induces Brain Endothelial Cell Permeability via CXCR2, PLoS ONE, vol.7, issue.9, p.45562, 2012.
DOI : 10.1371/journal.pone.0045562.t001

L. Guelte, A. Dwyer, J. Gavard, and J. , Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer, Biology of the Cell, vol.63, issue.12, pp.593-605, 2011.
DOI : 10.1042/BC20110069